Steve Williamson, MD

Professional Background

Dr. Stephen Williamson is certified by the American Board of Internal Medicine with a sub certification in medical oncology. He completed a fellowship at the University of Kansas Medical Center. He earned his medical degree from the University of Kansas School of Medicine and completed his residency at the University of Oklahoma, Tulsa Medical College. Dr. Williamson is committed to providing the most advanced cancer care and service for his patients. Dr. Williamson is also committed to training young physicians to become the best oncologists in the field. The treatment of cancer is constantly changing and improving. He has been dedicated to clinical research by designing and participating in clinical trials in order to help to make discoveries and improve treatments not only for his patients but for all patients. Dr. Williamson is committed to providing compassionate and cutting-edge care of patients with cancer using a multidisciplinary approach to provide comprehensive care within an environment that considers the patient's needs as the top priority.

• MD, Univ. of Kansas-Medical Ctr.
• Clinical Fellowship, Oncology, University of Kansas Medical Center, Kansas City, KS

• Diplomat in Subspecialty of Medical Oncology, American Board of Internal Medicine

• American Association for Cancer Research, Member, 2016 - Present
• Association of American Cancer Institutes, Steering Committee, Member, 2015 - Present
• Association of American Cancer Institutes, Member, 2010 - Present
• Health Volunteers Overseas, Member Number R 7122, Medical Physician, 2010 - Present
• Kansas Foundation for Medical Care, Inc., Member, 2002 - Present
• Central Society for Clinical Research, Member, 1996 - Present
• American College for Physicians, Fellow, 1992 - Present

---

Research

Overview

My primary areas of research interest over the years have been in the design, conduct, and analysis of Phase I, II, and III clinical trials evaluating new therapeutic agents and modalities in solid tumor patients. My focus has changed in that I am currently mentoring and assisting junior faculty with their clinical trials as opposed to writing and coordinating my own trials. I am currently focusing on inpatient cancer care.

• Modular phase 2 study to link combination immune- therapy to patients with advanced solid and hematologic malignancies, Novartis Pharmaceuticals Corp
• A multi-center, open-label, single-arm, dose-escalation, phase 1 clinical study to evaluate safety, tolerability, pharmacoklnetics (PK) and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors, Pending
• A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 Administered Alone or in Combination with REGN2810 in Patients with Advanced Malignancies, Regeneron Pharmaceuticals

• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. 2006. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 (21), 3347-53
• Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG. 2010. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (20), 3330-5
• Williamson SK, Crowley JJ, Lara, Jr PN, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR. 2005. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 (36), 9097-104
• Govindarajan R, Siegel E, Makhoul I, Williamson S. 2013. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.. American journal of clinical oncology, 36 (3), 254-7
• Williamson SK, Johnson GA, Maulhardt HA, Moore KM, McMeekin DS, Schulz TK, Reed GA, Roby KF, Mackay CB, Smith HJ, Weir SJ, Wick JA, Markman M, diZerega GS, Baltezor MJ, Espinosa J, Decedue CJ. 2015. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies.. Cancer chemotherapy and pharmacology, 75 (5), 1075-87
• Kalubowilage Madumali, Covarrubias-Zambrano Obdulia, Malalasekera Aruni P, Wendel Sebastian O, Wang Hongwang, Yapa Asanka S, Chlebanowski Lauren, Toledo Yubisela, Ortega Raquel, Janik Katharine E, Shrestha Tej B, Culbertson Christopher T, Kasi Anup, Williamson Stephen, Troyer Deryl L, Bossmann Stefan H. 2018. Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors. Nanomedicine: Nanotechnology, Biology and Medicine, 14 (6), 1823-1832. http://dx.doi.org/10.1016/j.nano.2018.04.020
• Abou-Alfa GK, Miksad RA, Tejani MA, Williamson S, Gutierrez ME, Olowokure OO, Sharma MR, El Dika I, Sherman ML, Pandya SS. 2019. A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.. The oncologist, 24 (2), 161-e70
• Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara, Jr PN, Coltman, Jr CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. 2009. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 (21), 3540-6
• Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, LeBlanc M, Urba SG. 2011. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.. Investigational new drugs, 29 (2), 352-9
• O'Connor Patrick, Bhadbhade Pooja, Khan Qamar, Williamson Stephen K. 2020. Acral vascular syndrome during an immune checkpoint inhibitor. BMJ. https://casereports.bmj.com/content/13/5/e233463.full